Evidence map›Paper›PMID 41589759›Full record

ArticleMuscle & nerve2026

Practical Approach to Managing SCIg Treatment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Tuan Vu, Claudia Guerra, Niraja Suresh, Sami Khella, Jamie Morrell, Michael Pulley, Nan Jiang, Khema Sharma, Tulio Bertorini, Nivedita Jerath and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tuan VuGBS/CIDP Center of Excellence, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.ORCID https://orcid.org/0000-0003-0724-0210
Claudia GuerraGBS/CIDP Center of Excellence, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Niraja SureshLakeland Regional Medical Center, Lakeland, Florida, USA.
Sami KhellaDepartment of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Jamie MorrellPromptCare, New Providence, New Jersey, USA.
Michael PulleyDepartment of Neurology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Nan JiangDepartment of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Khema SharmaNeurology Department, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Tulio BertoriniUniversity of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Nivedita JerathAdventHealth Neuroscience Institute, Orlando, Florida, USA.
Amanda PeltierNeuromuscular Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0003-1097-7715

Funding

CSL Behring
6 · The paper itself

Abstract

INTRODUCTION/

aimsGuidelines for the management of chronic inflammatory demyelinating polyneuropathy (CIDP) recommend corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange for first-line therapies and subcutaneous immunoglobulin (SCIg) as a maintenance option. Literature on clinical experience with SCIg in CIDP maintenance therapy is limited. This study outlines practical approaches to SCIg transition and management optimization, considering the varying dosing recommendations in prescribing information and clinical guidelines.

methodsThis retrospective, multicenter study analyzed anonymized patient medical records from eight US centers. Patients with CIDP who transitioned to SCIg were included, and clinical practices regarding SCIg therapy management were analyzed.

resultsThese 20 cases presented practical and clinical considerations for successful SCIg transition and maintenance. Switching decisions were guided by patient-physician assessment of treatment goals, benefits, and risks. The most common reason for switching (70%) was preference for site of care. Eight patients (40%) transitioned to a dose equivalent to their baseline IVIg dose. Overall, 12/19 patients (63%) remained stable following transition. Relapse-free rates were higher in patients who transitioned to a higher (67%) or lower (75%) than baseline dose versus those who received an equivalent dose (50%). All relapsed patients restabilized after increasing their SCIg dose. The final mean (SD) SCIg dose was 0.32 (0.15) g/kg/week. SCIg was well tolerated; 11 patients (55%) reported better tolerance versus IVIg. DISCUSSION: These patient cases provide practical guidance for SCIg therapy in CIDP maintenance, emphasizing individualized dosing strategies, ongoing monitoring, and patient-centered engagement. The findings help inform clinical decision-making to optimize long-term therapeutic outcomes.

Indexed as

ImmunoglobulinsImmunoglobulins, IntravenousImmunologic FactorsPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPlasma ExchangeRetrospective StudiesTreatment OutcomeImmunoglobulinsImmunoglobulins, IntravenousImmunologic Factorschronic inflammatory demyelinating polyneuropathy (CIDP)clinical practice evidenceHizentraIgPro20subcutaneous immunoglobulin (SCIg)

Identifiers

PMID41589759
PMCPMC13047952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.